US Pharma MarketingMeiraGTx strikes royalty deal; Fore
June 7 biotech news brief: MeiraGTx strikes $135M Oberland royalty deal, Fore upsizes Series D-2 to $110M, Kalohexis files for IPO, plus Teva and Agios updates. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
Plus, news about Kalohexis, Teva and Agios:
👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...
Source: Endpoints News